Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Analysis of the clinical antibacterial and antituberculosis pipeline.

Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S.

Lancet Infect Dis. 2018 Oct 15. pii: S1473-3099(18)30513-9. doi: 10.1016/S1473-3099(18)30513-9. [Epub ahead of print] Review.

PMID:
30337260
2.

Developing a new antibiotic for extensively drug-resistant pathogens: the case of plazomicin.

Theuretzbacher U, Paul M.

Clin Microbiol Infect. 2018 Aug 1. pii: S1198-743X(18)30538-X. doi: 10.1016/j.cmi.2018.07.020. [Epub ahead of print] No abstract available.

PMID:
30076976
3.

Concentration-dependent plasma protein binding: Expect the unexpected.

Nation RL, Theuretzbacher U, Tsuji BT; International Society of Anti-Infective Pharmacology (ISAP).

Eur J Pharm Sci. 2018 Sep 15;122:341-346. doi: 10.1016/j.ejps.2018.07.004. Epub 2018 Jul 3. Review.

PMID:
30026170
4.

Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.

Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S.

JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627.

5.

Colistin versus colistin plus meropenem for severe infections Authors' reply.

Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L.

Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. No abstract available.

PMID:
29695358
6.

Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations.

Årdal C, Baraldi E, Theuretzbacher U, Outterson K, Plahte J, Ciabuschi F, Røttingen JA.

J Pharm Policy Pract. 2018 Apr 5;11:8. doi: 10.1186/s40545-018-0135-0. eCollection 2018.

7.

Unavailability of old antibiotics threatens effective treatment for common bacterial infections.

Tängdén T, Pulcini C, Aagaard H, Balasegaram M, Hara GL, Nathwani D, Sharland M, Theuretzbacher U, Cars O.

Lancet Infect Dis. 2018 Mar;18(3):242-244. doi: 10.1016/S1473-3099(18)30075-6. No abstract available. Erratum in: Lancet Infect Dis. 2018 Feb 28;:.

PMID:
29485082
8.

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.

Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.

PMID:
29456043
9.

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group.

Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21.

PMID:
29276051
10.

Global antimicrobial resistance in Gram-negative pathogens and clinical need.

Theuretzbacher U.

Curr Opin Microbiol. 2017 Oct;39:106-112. doi: 10.1016/j.mib.2017.10.028. Epub 2017 Nov 15. Review.

PMID:
29154024
11.

β-lactam prolonged infusion: it's time to implement!

Paul M, Theuretzbacher U.

Lancet Infect Dis. 2018 Jan;18(1):13-14. doi: 10.1016/S1473-3099(17)30614-X. Epub 2017 Nov 5. No abstract available.

PMID:
29102323
12.

Market watch: Innovation in the preclinical antibiotic pipeline.

Theuretzbacher U, Savic M, Årdal C, Outterson K.

Nat Rev Drug Discov. 2017 Nov;16(11):744-745. doi: 10.1038/nrd.2017.195. Epub 2017 Oct 6. No abstract available.

PMID:
28983100
13.

New drugs - will they solve the problem of resistance to antibiotics?

Theuretzbacher U.

Clin Microbiol Infect. 2017 Oct;23(10):695-696. doi: 10.1016/j.cmi.2017.08.013. Epub 2017 Aug 19. No abstract available.

14.

Antibiotic innovation for future public health needs.

Theuretzbacher U.

Clin Microbiol Infect. 2017 Oct;23(10):713-717. doi: 10.1016/j.cmi.2017.06.020. Epub 2017 Jun 24. Review.

15.

Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development.

Theuretzbacher U, Årdal C, Harbarth S.

Infect Dis Rep. 2017 Mar 30;9(1):6836. doi: 10.4081/idr.2017.6836. eCollection 2017 Mar 30. Review.

16.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
17.

Erratum to 'Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia': [International Journal of Antimicrobial Agents 49/1 (2017) 98-101].

Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP); ReAct Working Group on Old Antibiotics.

Int J Antimicrob Agents. 2017 Apr;49(4):482. doi: 10.1016/j.ijantimicag.2017.02.006. Epub 2017 Mar 3. No abstract available.

PMID:
28264779
18.

Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia.

Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP), ReAct Working Group on Old Antibiotics.

Int J Antimicrob Agents. 2017 Jan;49(1):98-101. doi: 10.1016/j.ijantimicag.2016.09.029. Epub 2016 Nov 16. Erratum in: Int J Antimicrob Agents. 2017 Apr;49(4):482.

PMID:
27887966
19.

Market watch: Antibacterial innovation in European SMEs.

Theuretzbacher U.

Nat Rev Drug Discov. 2016 Dec;15(12):812-813. doi: 10.1038/nrd.2016.229. Epub 2016 Nov 18. No abstract available.

PMID:
27857138
20.

Closing the evidence gap in infectious disease: point-of-care randomization and informed consent.

Huttner A, Leibovici L, Theuretzbacher U, Huttner B, Paul M.

Clin Microbiol Infect. 2017 Feb;23(2):73-77. doi: 10.1016/j.cmi.2016.07.029. Epub 2016 Aug 3. Review.

Supplemental Content

Loading ...
Support Center